Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced that the companies...

Related Keywords

Japan ,Canada ,Tokyo ,United States ,American ,America ,Chris Boshoff ,Naoki Okamura ,Ahsan Arozullah ,Courtney Bugler ,Head Of Oncology Development ,American Urological Association Annual Meeting ,Astellas Pharma Inc ,Drug Administration ,Oncology Research ,American Society Of Clinical Oncology ,Carolina Urologic Research Center ,Pfizer Inc ,Exchange Commission ,Pfizer ,European Union ,Prnewswire Astellas Pharma Inc ,European Medicines Agency ,Medivation Inc ,Lab Abnormalities ,New Drug Application ,Priority Review ,Fast Track ,Real Time Oncology Review ,Neal Shore ,Chief Medical Officer ,Strategic Innovation ,Genesiscare United States ,Primary Investigator ,Urological Association Annual Meeting ,New England Journal ,Senior Vice President ,Oncology Development ,Chief Oncology Research ,Development Officer ,Executive Vice President ,Pfizer Led Phase ,South America ,High Risk Biochemical ,Reversible Encephalopathy Syndrome ,Fetal Toxicity The ,Full Prescribing Information ,Focus Area Approach ,Pfizer Oncology ,Astellas Pharma ,Annual Report ,Looking Information ,Factors That May Affect Future ,Clin Pract ,Accessed March ,Prostate Cancer ,North America ,